08/07/2025 – AB Science announces today the successful completion of a capital increase of a total gross amount of EUR 1.925 million subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitNextNext post:AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSRelated PostsAB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025AB Science announces EMA approval of Masivet shelf-life extension to 4 yearsJune 9, 2025
AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALSJuly 24, 2025
Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer, with biomarker-driven patient selection targeting population most likely to benefitJuly 4, 2025
AB Science provides an update on the renegotiation of loan repayment terms with its financial creditorsJune 30, 2025
New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s diseaseJune 23, 2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025
